Unlock instant, AI-driven research and patent intelligence for your innovation.

Intermediates of bupropion metabolites synthesis

a technology of intermediates and metabolites, which is applied in the preparation of amino-hyroxy compounds, carbonyl compounds, organic racemisation, etc., can solve the problems of complex array of chiral compounds, dose limitation, and racemic bupropion not being free of adverse effects

Inactive Publication Date: 2006-03-16
SEPACOR INC
View PDF43 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clearly, the metabolism of bupropion, which is complicated and poorly understood, results in a complex array of chiral compounds.
Unfortunately, racemic bupropion is not free of adverse effects.
Administration of the drug can cause seizures, especially in patients currently taking the monoamine oxidase inhibitor phenelzine.
These effects are dose limiting in a number of patients, and can be particularly dangerous for Parkinson's patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intermediates of bupropion metabolites synthesis
  • Intermediates of bupropion metabolites synthesis
  • Intermediates of bupropion metabolites synthesis

Examples

Experimental program
Comparison scheme
Effect test

example 1

5.1. Example 1

Synthesis of (S,S)-Hydroxybupropion

[0112] This synthesis, which follows that depicted in Scheme 5 of the Detailed Description, comprises three steps.

[0113] Z-1-(3-Chlorophenyl)-1-tert-butyldimethylsilyloxy-1-propene: A solution of LDA (33.0 mmol) in THF (100 mL) was cooled to −78° C. and HMPA (5 mL) was added. The ketone [1-(3-chlorophenyl)-propanone] (8.6 g) in THF (20 mL) was slowly added over 45 minutes to this rapidly stirring mixture. After an additional 3 minutes at −78° C., TBSCl (33.0 mL, 1.0 M in hexane) was added. This mixture was stirred at −78° C. for 5 minutes and allowed to warm to room temperature over 40 minutes. NaHCO3 (60 mL, saturated aqueous solution) was added and the mixture was extracted with CH2Cl2 (2×80 mL). The organic extracts were combined, washed with brine, dried over Mg2SO4 and concentrated to give a crude mixture. The product was purified by flash chromatography eluted with hexane / TEA (99.5 / 0.5), yielding 13.4 g product (Z / E ratio>99)....

example 2

5.2. Example 2

Synthesis of Optically Pure Hydroxybupropion

[0117] 3′-Chloro-2-bromo-propiophenone: To a solution of 3′-chloropropiophenone (50.0 g, 297 mmol) in acetonitrile (595 mL) was added bromine (16.67 mL, 327 mmol) at room temperature. The reddish-yellow solution was allowed to stir for 18 h at room temperature. The solution was concentrated in vacuo to provide a reddish solid. The crude material was dissolved in 400 mL of ethyl acetate and washed with 400 mL of water. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo to give 72.6 g (98%) of crude product. 1H NMR (CDCl3) δ 1.90 (d, J=6 Hz, 3H), 5.21 (q, J=6 Hz, 1H), 7.37-7.88 (m, 3H), 7.98 (s, 1H).

[0118] 2-Hydroxy-2-(3′-chlorophenyl)-3,5,5-trimethylmorpholine: To a solution of 3′-chloro-2-bromo-propiophenone (61.2 g, 247 mmol) in acetonitrile (752 mL) was added 2-amino-2-methyl-1-propanol (56.5 g, 630 mmol). The reaction mixture was allowed to reflux for 8 hours, then slowly cooled to room temperature....

example 3

5.3. Example 3

Synthesis of Optically Pure Dihydrobupropion

[0124] (Racemic Erythro)-Dihydrobupropion: A three-neck 1 L RBF was charged with 3.0 g (10.8 mmol) of racemic bupropion. To the flask was added 30 mL of dry toluene. The suspension was cooled to −78° C. and to it was slowly added 7.2 mL (23.7 mmol) of a 3.3 M solution of Red-Al. After stirring at −78° C. for 2 h, the reaction was allowed to slowly warm to 23° C. overnight. 5N NaOH was added to the reaction, and this stirred for 30 min. The layers were separated, and the organic layer was washed with water (100 mL). The organic layer was dried (MgSO4) and concentrated in vacua to provide 2.6 g (86%) of crude product (Erythro:Threo ratio: 15:1).

[0125] (Racemic Erythro)-Dihydrobupropion Hydrochloride: Crude erythro dihydrobupropion (2.5 g, 10.3 mmol) was dissolved in 25 mL of methyl tert-butyl ether. The solution was stirred at 0° C. as anhydrous 2N HCl in ether (7.76 mL, 15.5 mmol) was slowly added. After stirring for 1 h at ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
weight percentaaaaaaaaaa
weight percentaaaaaaaaaa
Login to View More

Abstract

Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.

Description

[0001] This application is a continuation-in-part of copending application Ser. No. 09 / 510,241, filed Feb. 22, 2000, which claims priority to provisional application No. 60 / 148,324, filed Aug. 11, 1999, and provisional application No. 60 / 122,277, filed Mar. 1, 1999, each of which is incorporated herein by reference.1. FIELD OF THE INVENTION [0002] This invention relates to the synthesis of, methods of using, and compositions comprising bupropion metabolites, their isomers, and salts thereof. 2. BACKGROUND OF THE INVENTION [0003] Bupropion, a racemic mixture of (+)- and (−)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone, is an antidepressant of the aminoketone class, which is described in U.S. Pat. Nos. 3,819,706 and 3,885,046. The hydrochloride salt of bupropion is sold under the tradenames WELLBUTRIN® and WELLBUTRIN SR® (Glaxo Wellcome Inc.) for the treatment of depression. Bupropion is also sold under the tradename ZYBAN® (Glaxo Wellcome Inc.) as a drug useful to achi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/537A61K31/133A61K9/08A61K9/10A61K9/70A61K31/00A61K31/135A61K31/137A61K31/165A61K31/415A61K31/4178A61K31/43A61K31/435A61K31/4375A61K31/439A61K31/4427A61K31/46A61K31/465A61K31/50A61K31/53A61K31/535A61K31/5375A61K45/00A61K45/06A61P1/08A61P13/00A61P13/10A61P15/10A61P25/00A61P25/08A61P25/16A61P25/20A61P25/24A61P25/28A61P25/34A61P43/00C07B57/00C07C45/51C07C45/63C07C49/76C07C49/807C07C49/82C07C49/84C07C213/00C07C215/30C07C225/16C07C317/14C07D265/32
CPCA61K31/00A61K31/135A61K31/137A61K31/165A61K31/415A61K31/43A61K31/435A61K31/46A61K31/465A61K31/50A61K31/53A61K31/535A61K31/537A61K31/5375A61K45/06C07B2200/07C07C45/511C07C45/63C07C49/84C07C69/76C07C213/00C07C215/30C07C225/16C07D265/32A61K2300/00C07C49/82C07C49/80A61P1/08A61P13/00A61P13/10A61P15/00A61P15/10A61P25/00A61P25/04A61P25/08A61P25/16A61P25/18A61P25/20A61P25/24A61P25/28A61P25/34A61P43/00
Inventor FANG, KEVIN QUNSENANAYAKE, CHRISANTHIA HUGHGROVER, PAUL
Owner SEPACOR INC